Wildon Farwell - Dec 9, 2022 Form 4 Insider Report for Dyne Therapeutics, Inc. (DYN)

Role: Chief Medical Officer
Signature: /s/ Richard Scalzo, Attorney-in-Fact
Stock symbol: DYN
Transactions as of: Dec 9, 2022
Transactions value $: -$6,826
Form type: 4
Date filed: 12/13/2022, 04:04 PM
Previous filing: Sep 15, 2022
Next filing: Mar 15, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	DYN	Common Stock	Award	$0	+36K	+55.62%	$0.00	101K	Dec 9, 2022	Direct	F1, F2
transaction	DYN	Common Stock	Sale	-$6.83K	-628	-0.62%	$10.87	100K	Dec 12, 2022	Direct	F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	DYN	Stock option (right to buy)	Award	$0	+56K		$0.00	56K	Dec 9, 2022	Common Stock	56K	$10.72	Direct	F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Consists of shares of Common Stock issuable under 36,000 restricted stock units ("RSUs"). Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in equal quarterly installments over four years with the first installment vesting on March 10, 2023.
F2	Includes 91,625 unvested RSUs.
F3	Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person.
F4	Includes 90,231 unvested RSUs.
F5	This option was granted on December 9, 2022. The shares underlying the option are scheduled to vest over four years in equal monthly installments through December 10, 2026.